Immatics Q1 Revenue at $7.61M, Below Consensus
Reports Q1 revenue $7.61M, consensus $10.41M. "Immatics is entering a pivotal period as we continue to progress toward the pre-specified interim and final analyses from the Phase 3 SUPRAME trial of anzu-cel and actively prepare for commercialization in 2027," said Harpreet Singh, Chief Executive Officer and Co-Founder of Immatics. "At the same time, we expect multiple meaningful clinical readouts across our PRAME franchise in 2026 that continue to validate PRAME as an important target across multiple solid cancers, extending well beyond melanoma, and across two different therapeutic modalities. Immatics today is a company defined not only by compelling science, but by a diversified late- and mid-stage clinical portfolio, growing commercial readiness, and a clear strategy to translate innovation into meaningful patient impact."
Trade with 70% Backtested Accuracy
Analyst Views on IMTX
About IMTX
About the author
Immatics Reports Q1 2023 Financial Results
- Financial Overview: Immatics reported a Q1 2023 GAAP EPS of -€0.43, indicating challenges in profitability and reflecting pressure in market competition.
- Revenue Decline: The company generated €7.61 million in revenue, a 59.0% year-over-year decrease, highlighting significant difficulties in sales and market demand that could impact future liquidity.
- Market Reaction: The poor financial performance may undermine investor confidence in Immatics, leading to increased stock price volatility and affecting the company's ability to secure funding in the biotechnology sector.
- Strategic Adjustments: Immatics is considering acquiring Anzu-Cel Floor to enhance market competitiveness through resource and technology integration, which, despite current financial challenges, could lay the groundwork for future growth.
Immatics' PRAME T-Cell Therapy Shows Remarkable Efficacy
- Successful Case Treatment: At the Hopp Children's Cancer Center, a 17-year-old with nephroblastoma achieved significant tumor reduction and marked regression of liver, lung, and brain metastases after receiving Immatics' PRAME T-cell therapy, with ongoing remission at six months post-treatment, highlighting the therapy's potential in pediatric cancers.
- Clinical Data Presentation: The patient experienced a deep anti-tumor response three months post-treatment, with PET scans and MRIs showing significant regression across all lesions, and liquid biopsy monitoring indicated no tumor-derived DNA, confirming molecular remission and underscoring the efficacy of PRAME T-cell therapy.
- Safety Assessment: Reported adverse events included manageable cytokine release syndrome, which resolved with multi-modal anti-cytokine therapy and corticosteroids, and the patient was in excellent physical condition at the six-month follow-up, indicating the therapy's safety and tolerability.
- Future Development Directions: Immatics plans to conduct clinical studies in Heidelberg targeting pediatric patients with PRAME-positive relapsed or refractory solid tumors to further evaluate the potential of PRAME T-cell therapies, aiming to provide new treatment options for children facing severe diseases.
Immatics Reports FY Earnings: Revenue and EPS Analysis
- Earnings Overview: Immatics reported a FY GAAP EPS of -€1.61, indicating challenges in profitability that may affect investor confidence and market perception.
- Revenue Performance: The company generated revenue of €48.2M, which, while showing growth, has not reversed the loss situation, highlighting the need for improved product commercialization in a competitive market.
- Market Reaction: Due to ongoing losses and failure to achieve profitability, the market remains cautious about Immatics' future prospects, potentially leading to increased stock price volatility and impacting the company's ability to raise funds.
- Strategic Transition: Immatics is working to transition its PRAME leader into commercial reality; despite financial challenges, successful commercialization could provide long-term growth potential for the company.
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
- Funding Scale: Immatics has announced the sale of 12,500,000 ordinary shares at $10 each, expected to raise $125 million, which will provide crucial funding for the company's clinical development initiatives.
- Underwriter Lineup: The offering is being managed by Jefferies, Leerink Partners, and Cantor, reflecting market confidence in Immatics' future growth and potentially enhancing its reputation in the biopharmaceutical sector.
- Transaction Timeline: The offering is expected to close on December 8, 2025, subject to customary closing conditions, allowing the company to quickly access funds to support its research projects.
- Market Reaction Expectations: This financing will bolster Immatics' research capabilities in precision targeting of PRAME, potentially enhancing its competitive position in cancer treatment, particularly in therapies targeting over 50 types of cancer.
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Immatics Showcases Promising Anti-Tumor Effects of Anzu-cel PRAME Cell Therapy for Metastatic Uveal Melanoma at ESMO 2025 Presidential Symposium
Clinical Trial Results: An ongoing Phase 1b trial of anzu-cel (PRAME cell therapy) in 16 patients with metastatic uveal melanoma shows a confirmed objective response rate of 67%, with a median duration of response of 11 months and median progression-free survival of 8.5 months.
Safety and Tolerability: Anzu-cel demonstrates a favorable tolerability profile, with manageable treatment-emergent adverse events primarily related to cytopenias and cytokine release syndrome, indicating its potential as a treatment option for this difficult-to-treat cancer.
Future Development: Due to the promising results, Immatics has initiated a Phase 2 cohort study for anzu-cel in metastatic uveal melanoma, aiming to expand its application in this area of high unmet medical need.
Company Overview: Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, with a robust pipeline of therapies aimed at various cancers, including ongoing trials for both uveal and cutaneous melanoma.
Immatics Reports Q1 2023 Financial Results
- Financial Overview: Immatics reported a Q1 2023 GAAP EPS of -€0.43, indicating challenges in profitability and reflecting pressure in market competition.
- Revenue Decline: The company generated €7.61 million in revenue, a 59.0% year-over-year decrease, highlighting significant difficulties in sales and market demand that could impact future liquidity.
- Market Reaction: The poor financial performance may undermine investor confidence in Immatics, leading to increased stock price volatility and affecting the company's ability to secure funding in the biotechnology sector.
- Strategic Adjustments: Immatics is considering acquiring Anzu-Cel Floor to enhance market competitiveness through resource and technology integration, which, despite current financial challenges, could lay the groundwork for future growth.
Immatics' PRAME T-Cell Therapy Shows Remarkable Efficacy
- Successful Case Treatment: At the Hopp Children's Cancer Center, a 17-year-old with nephroblastoma achieved significant tumor reduction and marked regression of liver, lung, and brain metastases after receiving Immatics' PRAME T-cell therapy, with ongoing remission at six months post-treatment, highlighting the therapy's potential in pediatric cancers.
- Clinical Data Presentation: The patient experienced a deep anti-tumor response three months post-treatment, with PET scans and MRIs showing significant regression across all lesions, and liquid biopsy monitoring indicated no tumor-derived DNA, confirming molecular remission and underscoring the efficacy of PRAME T-cell therapy.
- Safety Assessment: Reported adverse events included manageable cytokine release syndrome, which resolved with multi-modal anti-cytokine therapy and corticosteroids, and the patient was in excellent physical condition at the six-month follow-up, indicating the therapy's safety and tolerability.
- Future Development Directions: Immatics plans to conduct clinical studies in Heidelberg targeting pediatric patients with PRAME-positive relapsed or refractory solid tumors to further evaluate the potential of PRAME T-cell therapies, aiming to provide new treatment options for children facing severe diseases.
Immatics Reports FY Earnings: Revenue and EPS Analysis
- Earnings Overview: Immatics reported a FY GAAP EPS of -€1.61, indicating challenges in profitability that may affect investor confidence and market perception.
- Revenue Performance: The company generated revenue of €48.2M, which, while showing growth, has not reversed the loss situation, highlighting the need for improved product commercialization in a competitive market.
- Market Reaction: Due to ongoing losses and failure to achieve profitability, the market remains cautious about Immatics' future prospects, potentially leading to increased stock price volatility and impacting the company's ability to raise funds.
- Strategic Transition: Immatics is working to transition its PRAME leader into commercial reality; despite financial challenges, successful commercialization could provide long-term growth potential for the company.
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
- Funding Scale: Immatics has announced the sale of 12,500,000 ordinary shares at $10 each, expected to raise $125 million, which will provide crucial funding for the company's clinical development initiatives.
- Underwriter Lineup: The offering is being managed by Jefferies, Leerink Partners, and Cantor, reflecting market confidence in Immatics' future growth and potentially enhancing its reputation in the biopharmaceutical sector.
- Transaction Timeline: The offering is expected to close on December 8, 2025, subject to customary closing conditions, allowing the company to quickly access funds to support its research projects.
- Market Reaction Expectations: This financing will bolster Immatics' research capabilities in precision targeting of PRAME, potentially enhancing its competitive position in cancer treatment, particularly in therapies targeting over 50 types of cancer.
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
Immatics Showcases Promising Anti-Tumor Effects of Anzu-cel PRAME Cell Therapy for Metastatic Uveal Melanoma at ESMO 2025 Presidential Symposium
Clinical Trial Results: An ongoing Phase 1b trial of anzu-cel (PRAME cell therapy) in 16 patients with metastatic uveal melanoma shows a confirmed objective response rate of 67%, with a median duration of response of 11 months and median progression-free survival of 8.5 months.
Safety and Tolerability: Anzu-cel demonstrates a favorable tolerability profile, with manageable treatment-emergent adverse events primarily related to cytopenias and cytokine release syndrome, indicating its potential as a treatment option for this difficult-to-treat cancer.
Future Development: Due to the promising results, Immatics has initiated a Phase 2 cohort study for anzu-cel in metastatic uveal melanoma, aiming to expand its application in this area of high unmet medical need.
Company Overview: Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, with a robust pipeline of therapies aimed at various cancers, including ongoing trials for both uveal and cutaneous melanoma.
